Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial

Journal of Intensive Care

Volumn 5, Issue 1, 2017, Pages

  Iba, Toshiaki ^a   Fowler, Lucy ^a,b  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Endotoxin activity assay; Polymyxin B immobilized fiber column; Randomized controlled trial; Sepsis; Septic shock

Indexed keywords

POLYMYXIN B;

ANTISEPSIS; CARDIOVASCULAR FUNCTION; DISEASE SEVERITY; ENDOTOXEMIA; FLUID RESUSCITATION; HEMOPERFUSION; HUMAN; LETTER; MEAN ARTERIAL PRESSURE; MEDICAL DEVICE; MORTALITY; MULTIPLE ORGAN FAILURE; ORGAN DYSFUNCTION SCORE; POLYMYXIN B IMMOBILIZED FIBER COLUMN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SEPTIC SHOCK;

EID: 85021669734     PISSN: None     EISSN: 20520492     Source Type: Journal    
DOI: 10.1186/s40560-017-0236-x     Document Type: Letter

References (12)

1. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL, et al. Sepsis and septic shock. Nat Rev Dis Primer. 2016;2:16045.
2. Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol. 2016;103:253-61.
3. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47.
4. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445-52.
5. Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41:975-84.
6. Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials. 2014;15:218.
7. Chang T, Tu YK, Lee CT, Chao A, Huang CH, Wang MJ, Yeh YC. Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med. 2017. doi: 10.1097/CCM.0000000000002362.
8. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004;190:527-34.
9. Iwagami M, Yasunaga H, Noiri E, Horiguchi H, Fushimi K, Matsubara T, Yahagi N, Nangaku M, Doi K. Potential survival benefit of polymyxin B hemoperfusion in septic shock patients on continuous renal replacement therapy: a propensity-matched analysis. Blood Purif. 2016;42:9-17.
10. Saito N, Sugiyama K, Ohnuma T, Kanemura T, Nasu M, Yoshidomi Y, Tsujimoto Y, Adachi H, Koami H, Tochiki A, Hori K, Wagatsuma Y, Matsumoto H. Efficacy of polymyxin B-immobilized fiber hemoperfusion for patients with septic shock caused by Gram-negative bacillus infection. PLoS One. 2017;12, e0173633.
11. Nakamura Y, Kitamura T, Kiyomi F, Hayakawa M, Hoshino K, Kawano Y, Yamasaki R, Nishida T, Mizunuma M, Ishikura H. Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study. Crit Care. 2017;21:134.
12. Terayama T, Yamakawa K, Umemura Y, Aihara M, Fujimi S. Polymyxin B hemoperfusion for sepsis and septic shock: a systematic review and meta-analysis. Surg Infect. 2017;18:225-33.